既往研究表明，健脾益肺II号具有减少COPD患者急加重次数的作用，但机制尚不明确。COPD患者更易感冒，鼻病毒感染是诱发上呼吸道感染和COPD急性加重的重要原因之一。ICAM-1作为鼻病毒最主要的受体，介导了其对宿主的粘附和增殖过程。本研究拟将健脾益肺II号的抗病毒作用作为其预防COPD急性加重的切入点，一方面通过基因芯片技术筛选影响COPD小鼠鼻病毒易感性的生物标志物和健脾益肺II号的作用靶点，另一方面，通过体内和体外实验观察健脾益肺II号的直接抗病毒作用和减少COPD小鼠呼吸道鼻病毒复制的作用，并运用realtime PCR、western blot等技术研究其对PI3K/Akt/ICAM信号通路的影响，以揭示其抗病毒作用的机制。本研究将为健脾益肺II号的临床应用提供实验室依据，也为中药预防COPD稳定期急性加重的研究提供新的思路。

Previous study shows that JYII could prevent COPD patients from acute exacerbation,but the mechanism is unclear.COPD patients are susceptable to cold, and rhinovirous is the main pathogen in upper respiratory infection and COPD exacerbation.ICAM-1 is the receptor of rhinovirous,which imediate adherent and replication of virous.This study will focus on the antivitral effect of JYII to investigate into its mechanism of prevention from COPD exacerbation .Firstly,we will screen the gene and microRNA related to virus susceptibility ,also the target of JYII by gene microarray.Sencondly,we will observe the antivitral effect of JYII in vitro and vivo by flow cytometry,realtime PCR,western blot and so on.And we also study the PI3K/Akt pathway signaling on ICAM-1 expression and effect of JYII on it.Our study will provide laboratorial evidence for clinical apply of JYII,and provide a new idea to study the preventive effect on COPD exacerbation of Chinese Herb.